SEC Form 4 · accession 0001104659-15-071603
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mariam E Morris
Officer — Chief Financial Officer
Period of report
Oct 20, 2015
Accepted (ET)
Oct 20, 2015 · 2:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $6.49 | Oct 20, 2015 | A | 102,900 | A | — | Oct 19, 2024 | Common Stock | 102,900 | 102,900 | D |
Explanation of responses
- F1The Stock Option vests in four equal installments on October 20, 2016, 2017, 2018 and 2019.